[ CAS No. 1009820-21-6 ]

Name: 1009820-21-6|5-((3-Chlorophenyl)amino)benzo[c][2,6]naphthyridine-8-carboxylic acid|98%
Brand: Ambeed
SKU: A103748
Price: 6.0 USD
Availability: InStock
Rating: 91 (27 reviews)

{[proInfo.proName]} (Synonyms:Silmitasertib) ,{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]}

Structure of 1009820-21-6 * Storage: {[proInfo.prStorage]}

Cart0 Add to My Favorites Bulk Inquiry Add To Cart

* Storage: {[proInfo.prStorage]}

For Research Only 100K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 1009820-21-6 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 1009820-21-6 ]

SDS Specification

Alternatived Products of [ 1009820-21-6 ]

Product Details of [ 1009820-21-6 ]

CAS No. :	1009820-21-6	MDL No. :
Formula :	-	Boiling Point :	-
Linear Structure Formula :	-	InChI Key :	MUOKSQABCJCOPU-UHFFFAOYSA-N
M.W :	-	Pubchem ID :	24748573
Synonyms :	Silmitasertib

Calculated chemistry of [ 1009820-21-6 ]

Physicochemical Properties

Num. heavy atoms :	25
Num. arom. heavy atoms :	20
Fraction Csp3 :	0.0
Num. rotatable bonds :	3
Num. H-bond acceptors :	4.0
Num. H-bond donors :	2.0
Molar Refractivity :	98.56
TPSA :	75.11 Å²

Pharmacokinetics

GI absorption :	High
BBB permeant :	No
P-gp substrate :	No
CYP1A2 inhibitor :	Yes
CYP2C19 inhibitor :	Yes
CYP2C9 inhibitor :	Yes
CYP2D6 inhibitor :	Yes
CYP3A4 inhibitor :	No
Log Kp (skin permeation) :	-5.31 cm/s

Lipophilicity

Log Po/w (iLOGP) :	2.11
Log Po/w (XLOGP3) :	4.4
Log Po/w (WLOGP) :	4.88
Log Po/w (MLOGP) :	3.01
Log Po/w (SILICOS-IT) :	3.69
Consensus Log Po/w :	3.62

Druglikeness

Lipinski :	0.0
Ghose :	None
Veber :	0.0
Egan :	0.0
Muegge :	0.0
Bioavailability Score :	0.56

Water Solubility

Log S (ESOL) :	-5.17
Solubility :	0.00234 mg/ml ; 0.00000669 mol/l
Class :	Moderately soluble
Log S (Ali) :	-5.69
Solubility :	0.000707 mg/ml ; 0.00000202 mol/l
Class :	Moderately soluble
Log S (SILICOS-IT) :	-7.52
Solubility :	0.0000105 mg/ml ; 0.00000003 mol/l
Class :	Poorly soluble

Medicinal Chemistry

PAINS :	0.0 alert
Brenk :	1.0 alert
Leadlikeness :	1.0
Synthetic accessibility :	2.43

Safety of [ 1009820-21-6 ]

Signal Word:		Class:
Precautionary Statements:		UN#:
Hazard Statements:		Packing Group:

Application In Synthesis of [ 1009820-21-6 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Downstream synthetic route of [ 1009820-21-6 ]

[ 1009820-21-6 ] Synthesis Path-Downstream 1~49

1
[ 1009820-90-9 ]
[ 1009820-21-6 ]

Yield	Reaction Conditions	Operation in experiment
	With sodium hydroxide; water In methanol at 50℃; for 0.5h;	1.1 Methyl 5-chlorobenzo[c][2,6]naphthyridine-8-carboxylate (232 mg, 0.853 mmol) was combined with meto-chloroaniline (217 mg, 1.71 mmol) and N-methyl pyrrolidinone (1 mL) in a flask and the mixture was heated to 8O0C for 2 hours at which time LCMS indicated that the reaction was complete as indicated by the absence of any starting material. The mixture was dissolved in CH2CI2, washed with saturated aqueous sodium bicarbonate and dried over Na2SO4. The material was purified by flash chromatography (SiO2, 1:1 to 9:1 gradient of EtOAc/Hexanes) to obtain the ester. The material was dissolved in methanol and 6N aqueous NaOH and the mixture stirred at 500C for 30 minutes. The volatiles were removed in vacuo. The residue was triturated from acetic acid/THF/methanol using a mixture of hexanes and ethylacetate. Filtration and drying provided 147 mg of 5-(3- chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid. LCMS (ESI) 350 (M+l)+. 1HNMR (400 MHz, DMSOd6) δ 10.21 (s, IH), 9.72 (br s, IH), 9.02 (d, / = 5.6, IH), 8.89 (d, / = 8.8, IH), 8.62 (d, / = 5.6, IH), 8.31 (br s, IH), 8.28 (d, / = 1.6, IH), 8.10 (br d, / = 8, IH), 7.99 (dd, J = IJ = 8.4, IH), 7.46 (t, / = 8.0, IH), 7.16 (br d, / = 7.2, IH) ppm.
	Stage #1: methyl 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylate With water; sodium hydroxide In methanol at 50℃; for 0.5h; Stage #2: With acetic acid In tetrahydrofuran; methanol	1.1 Methyl 5-chlorobenzo[c][2,6]naphthyridine-8-carboxylate (232 mg, 0.853 mmol) was combined with meta-chloroaniline (217 mg, 1.71 mmol) and N-methylpyrrolidinone (1 mL) in a flask and the mixture was heated to 80° C. for 2 hours at which time LCMS indicated that the reaction was complete as indicated by the absence of any starting material. The mixture was dissolved in CH2Cl2, washed with saturated aqueous sodium bicarbonate and dried over Na2SO4. The material was purified by flash chromatography (SiO2, 1:1 to 9:1 gradient of EtOAc/Hexanes) to obtain the ester. The material was dissolved in methanol and 6N aqueous NaOH and the mixture stirred at 50° C. for 30 minutes. The volatiles were removed in vacuo. The residue was triturated from acetic acid/THF/methanol using a mixture of hexanes and ethylacetate. Filtration and drying provided 147 mg of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid. LCMS (ESI) 350 (M+1)+. 1HNMR (400 MHz, DMSO-d6) δ 10.21 (s, 1H), 9.72 (br s, 1H), 9.02 (d, J=5.6, 1H), 8.89 (d, J=8.8, 1H), 8.62 (d, J=5.6, 1H), 8.31 (br s, 1H), 8.28 (d, J=1.6, 1H), 8.10 (br d, J=8, 1H), 7.99 (dd, J=2, J=8.4, 1H), 7.46 (t, J=8.0, 1H), 7.16 (br d, J=7.2, 1H) ppm.
	With sodium hydroxide at 70℃;

Reference： [1]Current Patent Assignee: SENHWA BIOSCIENCES - WO2008/28168, 2008, A2 Location in patent: Page/Page column 62-63
[2]Current Patent Assignee: SENHWA BIOSCIENCES - US2009/239859, 2009, A1 Location in patent: Page/Page column 26
[3]Wang, Yuanjiang; Wang, Xinyi; Xu, Gang; Gou, Shaohua [Journal of Medicinal Chemistry, 2021, vol. 64, # 7, p. 4163 - 4178] Wang, Yuanjiang; Lv, Zhaodan; Chen, Feihong; Wang, Xing; Gou, Shaohua [Journal of Medicinal Chemistry, 2021, vol. 64, # 8, p. 5082 - 5098]

2
[ 1009820-21-6 ]
[ 1186037-14-8 ]

Yield	Reaction Conditions	Operation in experiment
	With ammonium chloride; benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In 1-methyl-pyrrolidin-2-one at 70℃;

Reference： [1]Location in patent: scheme or table Pierre, Fabrice; Stefan, Eric; Nédellec, Anne-Sophie; Chevrel, Marie-Claire; Regan, Collin F.; Siddiqui-Jain, Adam; MacAlino, Diwata; Streiner, Nicole; Drygin, Denis; Haddach, Mustapha; O'Brien, Sean E.; Anderes, Kenna; Ryckman, David M. [Bioorganic and Medicinal Chemistry Letters, 2011, vol. 21, # 22, p. 6687 - 6692]

3
[ 31246-66-9 ]
[ 1009820-21-6 ]
[ 1938132-55-8 ]

Yield	Reaction Conditions	Operation in experiment
40%	Stage #1: silmitasertib With O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate In N,N-dimethyl-formamide at 20℃; for 0.166667h; Stage #2: With triethylamine In N,N-dimethyl-formamide for 0.0833333h; Stage #3: cis,cis,trans-diamminedichlorodihydroxy platinum(IV) In N,N-dimethyl-formamide at 50℃; for 48h; Inert atmosphere;	1 Preparation of Compound 1 Preparation of Compound 1 wasThe 157.4mg (0.45mmol) CX-OH and 144.5mg (0.45mmol) TBTU was dissolved in 15mL of anhydrous DMF, stir chamberMix 10min, then added 45.5mg (0.45mmol) TEA, continue stirring for 5min, then added 150.0mg (0.45mmol) cis, cis, trans - [Pt (NH3) 2Cl2 (OH) 2], under nitrogen, 50 reaction 48h. The reaction was concentrated concentrate was separated by silica gel chromatography, eluting with dichloromethane and methanol mixed solvent (10:1) to give a yellow product 79.9mg, 40% yield.

Reference： [1]Current Patent Assignee: SOUTHEAST UNIVERSITY - CN105622674, 2016, A Location in patent: Paragraph 0053; 0054; 0056; 0072; 0073; 0074

4
[ 1009820-21-6 ]
[ 5390-04-5 ]
[ 2257422-61-8 ]

Yield	Reaction Conditions	Operation in experiment
	Stage #1: silmitasertib With O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate In acetone at 20℃; for 0.25h; Stage #2: With triethylamine In acetone at 20℃; for 0.25h; Stage #3: pent-1-yn-5-ol In acetone for 24h; Reflux;	4.2. General procedure for preparation General procedure: General synthetic procedure of alkyne derivatives 6. A solution ofCX-4945 (350.0 mg, 1.0 mmol) and TBTU (385.0 mg, 1.2 mmol) in20 mL of acetone was stirred at room temperature. After 15 min, excessTEA was added and the reaction mixture was stirred for another 15 min.Alkynol 5 (1.2 mmol) was then added and the reaction mixture waskept stirring under reflux for 24 h. The solvent was then removed byevaporation under reduced pressure, and DCM was added. The organiclayer was washed with saturated NaHCO3 solution twice and wateronce, and dried over sodium sulfate. The filtrate was concentrated under reduced pressure to give crude compounds 6a-d as yellow oil.Yields: 6a: 82.3%, 6b: 91.2%, 6c: 83.7%, 6d: 87.2%. The crude productswere used directly for the subsequent reaction without further purification.

Reference： [1]Chen, Hong; Chen, Feihong; Liu, Nannan; Wang, Xinyi; Gou, Shaohua [Bioorganic Chemistry, 2018, vol. 81, p. 536 - 544]

5
[ 1009820-21-6 ]
[ 63478-76-2 ]
[ 2254418-03-4 ]

Yield	Reaction Conditions	Operation in experiment
	Stage #1: silmitasertib With O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate In acetone at 20℃; for 0.25h; Stage #2: With triethylamine In acetone at 20℃; for 0.25h; Stage #3: 1-hydroxy-6-heptyne In acetone for 24h; Reflux;	4.2. General procedure for preparation General procedure: General synthetic procedure of alkyne derivatives 6. A solution ofCX-4945 (350.0 mg, 1.0 mmol) and TBTU (385.0 mg, 1.2 mmol) in20 mL of acetone was stirred at room temperature. After 15 min, excessTEA was added and the reaction mixture was stirred for another 15 min.Alkynol 5 (1.2 mmol) was then added and the reaction mixture waskept stirring under reflux for 24 h. The solvent was then removed byevaporation under reduced pressure, and DCM was added. The organiclayer was washed with saturated NaHCO3 solution twice and wateronce, and dried over sodium sulfate. The filtrate was concentrated under reduced pressure to give crude compounds 6a-d as yellow oil.Yields: 6a: 82.3%, 6b: 91.2%, 6c: 83.7%, 6d: 87.2%. The crude productswere used directly for the subsequent reaction without further purification.

Reference： [1]Chen, Hong; Chen, Feihong; Liu, Nannan; Wang, Xinyi; Gou, Shaohua [Bioorganic Chemistry, 2018, vol. 81, p. 536 - 544]

6
[ 3973-18-0 ]
silmitasertib [ No CAS ]
C₂₄H₁₈ClN₃O₃ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
		General procedure: General synthetic procedure of alkyne derivatives 6. A solution ofCX-4945 (350.0 mg, 1.0 mmol) and TBTU (385.0 mg, 1.2 mmol) in20 mL of acetone was stirred at room temperature. After 15 min, excessTEA was added and the reaction mixture was stirred for another 15 min.Alkynol 5 (1.2 mmol) was then added and the reaction mixture waskept stirring under reflux for 24 h. The solvent was then removed byevaporation under reduced pressure, and DCM was added. The organiclayer was washed with saturated NaHCO3 solution twice and wateronce, and dried over sodium sulfate. The filtrate was concentrated under reduced pressure to give crude compounds 6a-d as yellow oil.Yields: 6a: 82.3%, 6b: 91.2%, 6c: 83.7%, 6d: 87.2%. The crude productswere used directly for the subsequent reaction without further purification.

Reference： [1]Bioorganic Chemistry,2018,vol. 81,p. 536 - 544

7
[ 1009820-21-6 ]
[ CAS Unavailable ]
[ 2257422-60-7 ]

Yield	Reaction Conditions	Operation in experiment
	Stage #1: silmitasertib With O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate In acetone at 20℃; for 0.25h; Stage #2: With triethylamine In acetone at 20℃; for 0.25h; Stage #3: 3-Butyn-1-ol In acetone for 24h; Reflux;	4.2. General procedure for preparation General procedure: General synthetic procedure of alkyne derivatives 6. A solution ofCX-4945 (350.0 mg, 1.0 mmol) and TBTU (385.0 mg, 1.2 mmol) in20 mL of acetone was stirred at room temperature. After 15 min, excessTEA was added and the reaction mixture was stirred for another 15 min.Alkynol 5 (1.2 mmol) was then added and the reaction mixture waskept stirring under reflux for 24 h. The solvent was then removed byevaporation under reduced pressure, and DCM was added. The organiclayer was washed with saturated NaHCO3 solution twice and wateronce, and dried over sodium sulfate. The filtrate was concentrated under reduced pressure to give crude compounds 6a-d as yellow oil.Yields: 6a: 82.3%, 6b: 91.2%, 6c: 83.7%, 6d: 87.2%. The crude productswere used directly for the subsequent reaction without further purification.

Reference： [1]Chen, Hong; Chen, Feihong; Liu, Nannan; Wang, Xinyi; Gou, Shaohua [Bioorganic Chemistry, 2018, vol. 81, p. 536 - 544]

8
[ 1009820-21-6 ]
[ 2254407-01-5 ]

Yield	Reaction Conditions	Operation in experiment
	Multi-step reaction with 2 steps 1.1: O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate / acetone / 0.25 h / 20 °C 1.2: 0.25 h / 20 °C 1.3: 24 h / Reflux 2.1: copper(ll) sulfate pentahydrate; sodium L-ascorbate / water; tetrahydrofuran / 20 °C / Inert atmosphere

Reference： [1]Chen, Hong; Chen, Feihong; Liu, Nannan; Wang, Xinyi; Gou, Shaohua [Bioorganic Chemistry, 2018, vol. 81, p. 536 - 544]

9
[ 1009820-21-6 ]
[ 28625-06-1 ]
[ 1938132-56-9 ]

Yield	Reaction Conditions	Operation in experiment
	With O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate; triethylamine In N,N-dimethyl-formamide

Reference： [1]Chen, Feihong; Gou, Shaohua; Pei, Sinan; Wang, Xing; Zhu, Qian [Biochemical and Biophysical Research Communications, 2019]

10
[ 1009820-21-6 ]
[ 2095556-84-4 ]
[ 2459739-23-0 ]

Yield	Reaction Conditions	Operation in experiment
	With O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate; triethylamine In N,N-dimethyl-formamide

Reference： [1]Chen, Feihong; Gou, Shaohua; Pei, Sinan; Wang, Xing; Zhu, Qian [Biochemical and Biophysical Research Communications, 2019]

11
[ 1009820-21-6 ]
[ 2093416-32-9 ]
[ 2715987-68-9 ]

Yield	Reaction Conditions	Operation in experiment
57%	With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate In N,N-dimethyl-formamide at 20℃; for 1h; Inert atmosphere;

Reference： [1]Goracci, Laura; Desantis, Jenny; Valeri, Aurora; Castellani, Beatrice; Eleuteri, Michela; Cruciani, Gabriele [Journal of Medicinal Chemistry, 2020, vol. 63, # 20, p. 11615 - 11638]

12
[ 1009820-21-6 ]
[ 2411422-49-4 ]
[ 2715987-71-4 ]

Yield	Reaction Conditions	Operation in experiment
35%	With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate In N,N-dimethyl-formamide at 20℃; Inert atmosphere;

13
[ 1009820-21-6 ]
[ 1950635-15-0 ]
[ 2715987-65-6 ]

Yield	Reaction Conditions	Operation in experiment
42%	With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate In N,N-dimethyl-formamide at 20℃; Inert atmosphere;

14
[ 1009820-21-6 ]
[ 2460022-55-1 ]
[ 2715987-66-7 ]

Yield	Reaction Conditions	Operation in experiment
51%	With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate In N,N-dimethyl-formamide at 20℃; Inert atmosphere;

15
[ 1009820-21-6 ]
[ 1957236-20-2 ]
[ 2715987-67-8 ]

Yield	Reaction Conditions	Operation in experiment
42%	With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate In N,N-dimethyl-formamide at 20℃; Inert atmosphere;

16
[ 1009820-21-6 ]
[ 2093386-50-4 ]
[ 2715987-69-0 ]

Yield	Reaction Conditions	Operation in experiment
53%	With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate In N,N-dimethyl-formamide at 20℃; for 2h; Inert atmosphere;

17
[ 1009820-21-6 ]
[ 2138440-53-4 ]
[ 2715987-70-3 ]

Yield	Reaction Conditions	Operation in experiment
40%	With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate In N,N-dimethyl-formamide at 20℃; Inert atmosphere;

18
[ 1009820-21-6 ]
[ 2488296-65-5 ]
[ 2715987-72-5 ]

Yield	Reaction Conditions	Operation in experiment
27%	With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate In N,N-dimethyl-formamide at 20℃; for 2h; Inert atmosphere;

19
[ 1009820-21-6 ]
[ 2715987-86-1 ]
[ 2715987-73-6 ]

Yield	Reaction Conditions	Operation in experiment
55%	With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate In N,N-dimethyl-formamide at 20℃; for 2h; Inert atmosphere;

20
[ 13959-02-9 ]
[ 1009820-21-6 ]

Yield	Reaction Conditions	Operation in experiment
	Multi-step reaction with 5 steps 1: sulfuric acid / Reflux 2: caesium carbonate; palladium bis[bis(diphenylphosphino)ferrocene] dichloride / 1,4-dioxane / 100 °C / Inert atmosphere 3: trichlorophosphate / 110 °C 4: 1-methyl-pyrrolidin-2-one / 110 °C 5: sodium hydroxide / 70 °C
	Multi-step reaction with 5 steps 1: sulfuric acid / Reflux 2: caesium carbonate; (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride / 1,4-dioxane / 100 °C / Inert atmosphere 3: trichlorophosphate / 110 °C 4: 1-methyl-pyrrolidin-2-one / 110 °C 5: sodium hydroxide / 70 °C

Reference： [1]Wang, Yuanjiang; Wang, Xinyi; Xu, Gang; Gou, Shaohua [Journal of Medicinal Chemistry, 2021, vol. 64, # 7, p. 4163 - 4178]
[2]Wang, Yuanjiang; Lv, Zhaodan; Chen, Feihong; Wang, Xing; Gou, Shaohua [Journal of Medicinal Chemistry, 2021, vol. 64, # 8, p. 5082 - 5098]

21
[ 13959-01-8 ]
silmitasertib [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	Multi-step reaction with 4 steps 1: caesium carbonate; palladium bis[bis(diphenylphosphino)ferrocene] dichloride / 1,4-dioxane / 100 °C / Inert atmosphere 2: trichlorophosphate / 110 °C 3: 1-methyl-pyrrolidin-2-one / 110 °C 4: sodium hydroxide / 70 °C
	Multi-step reaction with 4 steps 1: caesium carbonate; (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride / 1,4-dioxane / 100 °C / Inert atmosphere 2: trichlorophosphate / 110 °C 3: 1-methyl-pyrrolidin-2-one / 110 °C 4: sodium hydroxide / 70 °C

22
[ 1009820-33-0 ]
[ 1009820-21-6 ]

Yield	Reaction Conditions	Operation in experiment
	Multi-step reaction with 3 steps 1: trichlorophosphate / 110 °C 2: 1-methyl-pyrrolidin-2-one / 110 °C 3: sodium hydroxide / 70 °C

Reference： [1]Wang, Yuanjiang; Wang, Xinyi; Xu, Gang; Gou, Shaohua [Journal of Medicinal Chemistry, 2021, vol. 64, # 7, p. 4163 - 4178] Wang, Yuanjiang; Lv, Zhaodan; Chen, Feihong; Wang, Xing; Gou, Shaohua [Journal of Medicinal Chemistry, 2021, vol. 64, # 8, p. 5082 - 5098]

23
[ 1009826-84-9 ]
[ 1009820-21-6 ]

Yield	Reaction Conditions	Operation in experiment
	Multi-step reaction with 2 steps 1: 1-methyl-pyrrolidin-2-one / 110 °C 2: sodium hydroxide / 70 °C

24
[ 1009820-21-6 ]
[ 3144-09-0 ]
[ 2641079-91-4 ]

Yield	Reaction Conditions	Operation in experiment
43.5%	Stage #1: silmitasertib With HATU In N,N-dimethyl-formamide at 20℃; for 0.166667h; Inert atmosphere; Stage #2: With N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide at 20℃; for 0.166667h; Inert atmosphere; Stage #3: methanesulfonamide In N,N-dimethyl-formamide at 20℃; Inert atmosphere;
43.5%	With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate In N,N-dimethyl-formamide at 45℃; for 24h;	3 Example 3: Preparation of Compound 3 Add 0.174g (0.5mmol) of CX-4945, 0.048g (0.5mmol) of methanesulfonamide,HATU 0.228g (0.6mmol), DIPEA 0.129g (1mmol) and anhydrous DMF 5mL, stirred at 45°C for 24h,TLC monitors until the reaction is complete, the solvent is spin-dried in vacuo, and purified by silica gel column chromatography. The eluent is dichloromethane and methanol (100:1-50:1) to obtain 0.093 g of a yellow solid product with a yield of 43.5%

Reference： [1]Wang, Yuanjiang; Lv, Zhaodan; Chen, Feihong; Wang, Xing; Gou, Shaohua [Journal of Medicinal Chemistry, 2021, vol. 64, # 8, p. 5082 - 5098]
[2]Current Patent Assignee: SOUTHEAST UNIVERSITY - CN113444084, 2021, A Location in patent: Paragraph 0132; 0133

25
[ 1009820-21-6 ]
[ CAS Unavailable ]
[ 2641079-92-5 ]

Yield	Reaction Conditions	Operation in experiment
72.1%	Stage #1: silmitasertib With HATU In N,N-dimethyl-formamide at 20℃; for 0.166667h; Inert atmosphere; Stage #2: With N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide at 20℃; for 0.166667h; Inert atmosphere; Stage #3: ethanolamine In N,N-dimethyl-formamide at 20℃; Inert atmosphere;

Reference： [1]Wang, Yuanjiang; Lv, Zhaodan; Chen, Feihong; Wang, Xing; Gou, Shaohua [Journal of Medicinal Chemistry, 2021, vol. 64, # 8, p. 5082 - 5098]

26
[ 1009820-21-6 ]
[ 107-15-3 ]
[ 1186037-42-2 ]

Yield	Reaction Conditions	Operation in experiment
81.6%	Stage #1: silmitasertib With HATU In N,N-dimethyl-formamide at 20℃; for 0.166667h; Inert atmosphere; Stage #2: With N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide at 20℃; for 0.166667h; Inert atmosphere; Stage #3: ethylenediamine In N,N-dimethyl-formamide at 20℃; Inert atmosphere;

Reference： [1]Wang, Yuanjiang; Lv, Zhaodan; Chen, Feihong; Wang, Xing; Gou, Shaohua [Journal of Medicinal Chemistry, 2021, vol. 64, # 8, p. 5082 - 5098]

27
[ 107-09-5 ]
[ 1009820-21-6 ]
[ 2641079-93-6 ]

Yield	Reaction Conditions	Operation in experiment
61.4%	Stage #1: silmitasertib With HATU In N,N-dimethyl-formamide at 20℃; for 0.166667h; Inert atmosphere; Stage #2: With N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide at 20℃; for 0.166667h; Inert atmosphere; Stage #3: 2-bromoethylamine In N,N-dimethyl-formamide at 20℃; Inert atmosphere;

Reference： [1]Wang, Yuanjiang; Lv, Zhaodan; Chen, Feihong; Wang, Xing; Gou, Shaohua [Journal of Medicinal Chemistry, 2021, vol. 64, # 8, p. 5082 - 5098]

28
[ 1009820-21-6 ]
[ CAS Unavailable ]
[ 2641079-94-7 ]

Yield	Reaction Conditions	Operation in experiment
61.8%	Stage #1: silmitasertib With HATU In N,N-dimethyl-formamide at 20℃; for 0.166667h; Inert atmosphere; Stage #2: With N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide at 20℃; for 0.166667h; Inert atmosphere; Stage #3: 2,2-difluorethylamine In N,N-dimethyl-formamide at 20℃; Inert atmosphere;

Reference： [1]Wang, Yuanjiang; Lv, Zhaodan; Chen, Feihong; Wang, Xing; Gou, Shaohua [Journal of Medicinal Chemistry, 2021, vol. 64, # 8, p. 5082 - 5098]

29
[ 1009820-21-6 ]
[ 108-00-9 ]
[ 2641079-95-8 ]

Yield	Reaction Conditions	Operation in experiment
69.8%	Stage #1: silmitasertib With HATU In N,N-dimethyl-formamide at 20℃; for 0.166667h; Inert atmosphere; Stage #2: With N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide at 20℃; for 0.166667h; Inert atmosphere; Stage #3: N,N-dimethylethylenediamine In N,N-dimethyl-formamide at 20℃; Inert atmosphere;

Reference： [1]Wang, Yuanjiang; Lv, Zhaodan; Chen, Feihong; Wang, Xing; Gou, Shaohua [Journal of Medicinal Chemistry, 2021, vol. 64, # 8, p. 5082 - 5098]

30
[ 1009820-21-6 ]
[ CAS Unavailable ]
[ 2641079-96-9 ]

Yield	Reaction Conditions	Operation in experiment
76.4%	Stage #1: silmitasertib With HATU In N,N-dimethyl-formamide at 20℃; for 0.166667h; Inert atmosphere; Stage #2: With N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide at 20℃; for 0.166667h; Inert atmosphere; Stage #3: Propargylamine In N,N-dimethyl-formamide at 20℃; Inert atmosphere;

Reference： [1]Wang, Yuanjiang; Lv, Zhaodan; Chen, Feihong; Wang, Xing; Gou, Shaohua [Journal of Medicinal Chemistry, 2021, vol. 64, # 8, p. 5082 - 5098]

31
[ 1009820-21-6 ]
[ 4138-35-6 ]
[ 2641079-97-0 ]

Yield	Reaction Conditions	Operation in experiment
65.4%	Stage #1: silmitasertib With HATU In N,N-dimethyl-formamide at 20℃; for 0.166667h; Inert atmosphere; Stage #2: With N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide at 20℃; for 0.166667h; Inert atmosphere; Stage #3: methyl 3-aminopropanoate In N,N-dimethyl-formamide at 20℃; Inert atmosphere;

Reference： [1]Wang, Yuanjiang; Lv, Zhaodan; Chen, Feihong; Wang, Xing; Gou, Shaohua [Journal of Medicinal Chemistry, 2021, vol. 64, # 8, p. 5082 - 5098]

32
[ 7154-73-6 ]
[ 1009820-21-6 ]
[ 2641079-98-1 ]

Yield	Reaction Conditions	Operation in experiment
72.8%	Stage #1: silmitasertib With HATU In N,N-dimethyl-formamide at 20℃; for 0.166667h; Inert atmosphere; Stage #2: With N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide at 20℃; for 0.166667h; Inert atmosphere; Stage #3: 1-(2-aminoethyl)pyrrolidine In N,N-dimethyl-formamide at 20℃; Inert atmosphere;

Reference： [1]Wang, Yuanjiang; Lv, Zhaodan; Chen, Feihong; Wang, Xing; Gou, Shaohua [Journal of Medicinal Chemistry, 2021, vol. 64, # 8, p. 5082 - 5098]

33
[ 27578-60-5 ]
[ 1009820-21-6 ]
[ 2641079-99-2 ]

Yield	Reaction Conditions	Operation in experiment
77.1%	Stage #1: silmitasertib With HATU In N,N-dimethyl-formamide at 20℃; for 0.166667h; Inert atmosphere; Stage #2: With N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide at 20℃; for 0.166667h; Inert atmosphere; Stage #3: 1-(2-aminoethyl)piperidine In N,N-dimethyl-formamide at 20℃; Inert atmosphere;

Reference： [1]Wang, Yuanjiang; Lv, Zhaodan; Chen, Feihong; Wang, Xing; Gou, Shaohua [Journal of Medicinal Chemistry, 2021, vol. 64, # 8, p. 5082 - 5098]

34
[ 2038-03-1 ]
[ 1009820-21-6 ]
[ 1186037-30-8 ]

Yield	Reaction Conditions	Operation in experiment
68.7%	Stage #1: silmitasertib With HATU In N,N-dimethyl-formamide at 20℃; for 0.166667h; Inert atmosphere; Stage #2: With N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide at 20℃; for 0.166667h; Inert atmosphere; Stage #3: 4-(2-AMINOETHYL)MORPHOLINE In N,N-dimethyl-formamide at 20℃; Inert atmosphere;

Reference： [1]Wang, Yuanjiang; Lv, Zhaodan; Chen, Feihong; Wang, Xing; Gou, Shaohua [Journal of Medicinal Chemistry, 2021, vol. 64, # 8, p. 5082 - 5098]

35
[ 1009820-21-6 ]
[ CAS Unavailable ]
[ 2641080-00-2 ]

Yield	Reaction Conditions	Operation in experiment
79.8%	Stage #1: silmitasertib With HATU In N,N-dimethyl-formamide at 20℃; for 0.166667h; Inert atmosphere; Stage #2: With N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide at 20℃; for 0.166667h; Inert atmosphere; Stage #3: propan-1-ol-3-amine In N,N-dimethyl-formamide at 20℃; Inert atmosphere;

Reference： [1]Wang, Yuanjiang; Lv, Zhaodan; Chen, Feihong; Wang, Xing; Gou, Shaohua [Journal of Medicinal Chemistry, 2021, vol. 64, # 8, p. 5082 - 5098]

36
[ 1009820-21-6 ]
[ 109-76-2 ]
[ 2641080-01-3 ]

Yield	Reaction Conditions	Operation in experiment
57.3%	Stage #1: silmitasertib With HATU In N,N-dimethyl-formamide at 20℃; for 0.166667h; Inert atmosphere; Stage #2: With N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide at 20℃; for 0.166667h; Inert atmosphere; Stage #3: Trimethylenediamine In N,N-dimethyl-formamide at 20℃; Inert atmosphere;

Reference： [1]Wang, Yuanjiang; Lv, Zhaodan; Chen, Feihong; Wang, Xing; Gou, Shaohua [Journal of Medicinal Chemistry, 2021, vol. 64, # 8, p. 5082 - 5098]

37
[ 1009820-21-6 ]
[ 3251-07-8 ]
[ 2641080-02-4 ]

Yield	Reaction Conditions	Operation in experiment
65.8%	Stage #1: silmitasertib With HATU In N,N-dimethyl-formamide at 20℃; for 0.166667h; Inert atmosphere; Stage #2: With N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide at 20℃; for 0.166667h; Inert atmosphere; Stage #3: methyl 4-aminobutyrate In N,N-dimethyl-formamide at 20℃; Inert atmosphere;

Reference： [1]Wang, Yuanjiang; Lv, Zhaodan; Chen, Feihong; Wang, Xing; Gou, Shaohua [Journal of Medicinal Chemistry, 2021, vol. 64, # 8, p. 5082 - 5098]

38
[ 1009820-21-6 ]
[ 107-21-1 ]
[ 2641080-05-7 ]

Yield	Reaction Conditions	Operation in experiment
86.5%	Stage #1: silmitasertib With O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate In N,N-dimethyl-formamide at 45℃; for 0.166667h; Inert atmosphere; Stage #2: With triethylamine In N,N-dimethyl-formamide at 45℃; for 0.166667h; Inert atmosphere; Stage #3: ethylene glycol In N,N-dimethyl-formamide for 24h; Inert atmosphere;
86.5%	Stage #1: silmitasertib With O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate In N,N-dimethyl-formamide at 50℃; for 0.25h; Stage #2: With triethylamine In N,N-dimethyl-formamide for 0.25h; Stage #3: ethylene glycol In N,N-dimethyl-formamide for 24h;	19 Example 19: Preparation of Compound 19 Add 0.174g (0.5mmol) of CX-4945, 0.193g (0.6mmol) of TBTU and 5mL of anhydrous DMF into a 10mL single-neck flask, and stir for 15min at 50.Add TEA 0.101g (1.0mmol) and continue to stir for 15min, then add ethylene glycol 0.064g (1mmol) to react for 24h,TLC monitors until the reaction is complete, concentrate the solvent, and purify by silica gel column chromatography. The eluent is dichloromethane and methanol (100:1-50:1) to obtain 0.170g of yellow solid product with a yield of 86.5%

39
[ 624-76-0 ]
[ 1009820-21-6 ]
[ 2641080-06-8 ]

Yield	Reaction Conditions	Operation in experiment
77.3%	Stage #1: silmitasertib With O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate In N,N-dimethyl-formamide at 45℃; for 0.166667h; Inert atmosphere; Stage #2: With triethylamine In N,N-dimethyl-formamide at 45℃; for 0.166667h; Inert atmosphere; Stage #3: Iodoethanol In N,N-dimethyl-formamide for 24h; Inert atmosphere;

Reference： [1]Wang, Yuanjiang; Lv, Zhaodan; Chen, Feihong; Wang, Xing; Gou, Shaohua [Journal of Medicinal Chemistry, 2021, vol. 64, # 8, p. 5082 - 5098]

40
[ 1009820-21-6 ]
[ 371-62-0 ]
[ 2641080-07-9 ]

Yield	Reaction Conditions	Operation in experiment
82.8%	Stage #1: silmitasertib With O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate In N,N-dimethyl-formamide at 45℃; for 0.166667h; Inert atmosphere; Stage #2: With triethylamine In N,N-dimethyl-formamide at 45℃; for 0.166667h; Inert atmosphere; Stage #3: 2-fluoroethanol In N,N-dimethyl-formamide for 24h; Inert atmosphere;

Reference： [1]Wang, Yuanjiang; Lv, Zhaodan; Chen, Feihong; Wang, Xing; Gou, Shaohua [Journal of Medicinal Chemistry, 2021, vol. 64, # 8, p. 5082 - 5098]

41
[ 103-74-2 ]
[ 1009820-21-6 ]
[ 2641080-08-0 ]

Yield	Reaction Conditions	Operation in experiment
77.2%	Stage #1: silmitasertib With O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate In N,N-dimethyl-formamide at 45℃; for 0.166667h; Inert atmosphere; Stage #2: With triethylamine In N,N-dimethyl-formamide at 45℃; for 0.166667h; Inert atmosphere; Stage #3: 2-(2-Hydroxyethyl)pyridine In N,N-dimethyl-formamide for 24h; Inert atmosphere;

Reference： [1]Wang, Yuanjiang; Lv, Zhaodan; Chen, Feihong; Wang, Xing; Gou, Shaohua [Journal of Medicinal Chemistry, 2021, vol. 64, # 8, p. 5082 - 5098]

42
[ 1009820-21-6 ]
[ 359-13-7 ]
[ 2641080-09-1 ]

Yield	Reaction Conditions	Operation in experiment
65.7%	Stage #1: silmitasertib With O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate In N,N-dimethyl-formamide at 45℃; for 0.166667h; Inert atmosphere; Stage #2: With triethylamine In N,N-dimethyl-formamide at 45℃; for 0.166667h; Inert atmosphere; Stage #3: difluoroethanol In N,N-dimethyl-formamide for 24h; Inert atmosphere;

Reference： [1]Wang, Yuanjiang; Lv, Zhaodan; Chen, Feihong; Wang, Xing; Gou, Shaohua [Journal of Medicinal Chemistry, 2021, vol. 64, # 8, p. 5082 - 5098]

43
[ 1009820-21-6 ]
[ 83682-72-8 ]
[ 2641080-10-4 ]

Yield	Reaction Conditions	Operation in experiment
61.5%	Stage #1: silmitasertib With O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate In N,N-dimethyl-formamide at 45℃; for 0.166667h; Inert atmosphere; Stage #2: With triethylamine In N,N-dimethyl-formamide at 45℃; for 0.166667h; Inert atmosphere; Stage #3: γ,γ-dichloropropanol In N,N-dimethyl-formamide for 24h; Inert atmosphere;

Reference： [1]Wang, Yuanjiang; Lv, Zhaodan; Chen, Feihong; Wang, Xing; Gou, Shaohua [Journal of Medicinal Chemistry, 2021, vol. 64, # 8, p. 5082 - 5098]

44
[ 1009820-21-6 ]
[ 112-27-6 ]
[ 2641080-11-5 ]

Yield	Reaction Conditions	Operation in experiment
72.6%	Stage #1: silmitasertib With O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate In N,N-dimethyl-formamide at 45℃; for 0.166667h; Inert atmosphere; Stage #2: With triethylamine In N,N-dimethyl-formamide at 45℃; for 0.166667h; Inert atmosphere; Stage #3: 2,2'-[1,2-ethanediylbis(oxy)]bisethanol In N,N-dimethyl-formamide for 24h; Inert atmosphere;

Reference： [1]Wang, Yuanjiang; Lv, Zhaodan; Chen, Feihong; Wang, Xing; Gou, Shaohua [Journal of Medicinal Chemistry, 2021, vol. 64, # 8, p. 5082 - 5098]

45
[ 1009820-21-6 ]
[ 2641080-03-5 ]

Yield	Reaction Conditions	Operation in experiment
	Multi-step reaction with 2 steps 1.1: HATU / N,N-dimethyl-formamide / 0.17 h / 20 °C / Inert atmosphere 1.2: 0.17 h / 20 °C / Inert atmosphere 1.3: 20 °C / Inert atmosphere 2.1: lithium hydroxide monohydrate / methanol; water / 60 °C

Reference： [1]Wang, Yuanjiang; Lv, Zhaodan; Chen, Feihong; Wang, Xing; Gou, Shaohua [Journal of Medicinal Chemistry, 2021, vol. 64, # 8, p. 5082 - 5098]

46
[ 1009820-21-6 ]
[ 2641080-04-6 ]

Yield	Reaction Conditions	Operation in experiment
	Multi-step reaction with 2 steps 1.1: HATU / N,N-dimethyl-formamide / 0.17 h / 20 °C / Inert atmosphere 1.2: 0.17 h / 20 °C / Inert atmosphere 1.3: 20 °C / Inert atmosphere 2.1: lithium hydroxide monohydrate / methanol; water / 60 °C

Reference： [1]Wang, Yuanjiang; Lv, Zhaodan; Chen, Feihong; Wang, Xing; Gou, Shaohua [Journal of Medicinal Chemistry, 2021, vol. 64, # 8, p. 5082 - 5098]

47
[ 1009820-21-6 ]
[ CAS Unavailable ]
[ CAS Unavailable ]

Yield	Reaction Conditions	Operation in experiment
	With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate In N,N-dimethyl-formamide at 50℃;

Reference： [1]Current Patent Assignee: SOUTHEAST UNIVERSITY - CN113444084, 2021, A Location in patent: Paragraph 0087

48
[ 1009820-21-6 ]
[ 2576-47-8 ]
[ 2641079-93-6 ]

Yield	Reaction Conditions	Operation in experiment
61.4%	With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate In N,N-dimethyl-formamide at 50℃; for 24h;	6 Example 6: Preparation of Compound 6 Add 0.174g (0.5mmol) of CX-4945, 0.102g (0.5mmol) of 2-bromoethylamine hydrobromide,HATU 0.228g (0.6mmol), DIPEA 0.194g (1.5mmol) and anhydrous DMF 5mL, stir at 50 °C for 24h,TLC monitors until the reaction is complete, concentrate the solvent, and purify by silica gel column chromatography. The eluent is dichloromethane and methanol (100:1-50:1) to obtain 0.139g of yellow solid product with a yield of 61.4%

Reference： [1]Current Patent Assignee: SOUTHEAST UNIVERSITY - CN113444084, 2021, A Location in patent: Paragraph 0138; 0139

49
[ 1009820-21-6 ]
[ CAS Unavailable ]
[ CAS Unavailable ]

Yield	Reaction Conditions	Operation in experiment
	With O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate; triethylamine In N,N-dimethyl-formamide at 50℃;

Reference： [1]Current Patent Assignee: SOUTHEAST UNIVERSITY - CN113444084, 2021, A Location in patent: Paragraph 0089

Same Skeleton Products

Related Products

Historical Records

Ghs Precautionary Statements

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Purity	Size	Price	VIP Price	USA Stock *0-1 Day	Global Stock *5-7 Days	Quantity
{[ item.p_purity ]}	{[ item.pr_size ]}	{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]}	{[ getRatePrice(item.pr_usd, 1,1) ]}	{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]}	{[ item.pr_usastock ]}	Inquiry -	{[ item.pr_chinastock ]}	Inquiry -

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed
H304	May be fatal if swallowed and enters airways
H305	May be harmful if swallowed and enters airways
H310	Fatal in contact with skin
H311	Toxic in contact with skin
H312	Harmful in contact with skin
H313	May be harmful in contact with skin
H314	Causes severe skin burns and eye damage
H315	Causes skin irritation
H316	Causes mild skin irritation
H317	May cause an allergic skin reaction
H318	Causes serious eye damage
H319	Causes serious eye irritation
H320	Causes eye irritation
H330	Fatal if inhaled
H331	Toxic if inhaled
H332	Harmful if inhaled
H333	May be harmful if inhaled
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled
H335	May cause respiratory irritation
H336	May cause drowsiness or dizziness
H340	May cause genetic defects
H341	Suspected of causing genetic defects
H350	May cause cancer
H351	Suspected of causing cancer
H360	May damage fertility or the unborn child
H361	Suspected of damaging fertility or the unborn child
H361d	Suspected of damaging the unborn child
H362	May cause harm to breast-fed children
H370	Causes damage to organs
H371	May cause damage to organs
H372	Causes damage to organs through prolonged or repeated exposure
H373	May cause damage to organs through prolonged or repeated exposure
Environmental hazards
Code	Phrase
H400	Very toxic to aquatic life
H401	Toxic to aquatic life
H402	Harmful to aquatic life
H410	Very toxic to aquatic life with long-lasting effects
H411	Toxic to aquatic life with long-lasting effects
H412	Harmful to aquatic life with long-lasting effects
H413	May cause long-lasting harmful effects to aquatic life
H420	Harms public health and the environment by destroying ozone in the upper atmosphere

[ CAS No. 1009820-21-6 ]

Quality Control of [ 1009820-21-6 ]

Related Doc. of [ 1009820-21-6 ]

Product Details of [ 1009820-21-6 ]

Calculated chemistry of [ 1009820-21-6 ]

Physicochemical Properties

Pharmacokinetics

Lipophilicity

Druglikeness

Water Solubility

Medicinal Chemistry

Safety of [ 1009820-21-6 ]

Application In Synthesis of [ 1009820-21-6 ]

[ 1009820-21-6 ] Synthesis Path-Downstream 1~49

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry